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Abstract 
Background: Systemic reactions (SR) to venom immunotherapy (VIT) are rare but may occur, with a rate significantly 
higher for honeybee than for vespid VIT. In patients with repeated SRs to VIT it is difficult to reach the maintenance 
dose of venom and pre-treatment with omalizumab is indicated, as shown by some studies reporting its preventative 
capacity, when antihistamines and corticosteroids are ineffective.
Case presentation: We present the case of a 47 years old woman allergic to bee venom who experienced two 
severe SRs after bee stings and several SRs to VIT with bee venom. Pre-treatment with antihistamines and corticos-
teroids as well as omalizumab at doses up to 300 mg was unsuccessful, while an omalizumab dose of 450 mg finally 
achieved in our patient the protection from SRs to VIT with 200 mcg of bee venom.
Conclusions: The search of the dose of omalizumab able to protect a patient with repeated SRs to VIT may be 
demanding, but this search is warranted by the need to provide to this kind of patient, by an adequate VIT, the protec-
tion from potentially life-threatening reactions.
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Background
Venom immunotherapy (VIT) is generally safe and, 
differently from injective immunotherapy with inhal-
ant allergens, no fatal reaction to treatment has been 
reported [1]. Still, systemic reactions (SR) may occur, 
with a rate significantly higher for honeybee than for 
vespid VIT. In fact, a systematic review defined a rate of 
SRs of 25.1 % for honeybee VIT and 5.8 % for vespid VIT 
[2]. In patients with repeated SRs it is difficult to reach 
the maintenance dose of venom, usually corresponding 
to 100 mcg [1]. Mild to moderate SRs may be averted by 
pre-treatment with antihistamines [3], while for severe 
SRs pre-treatment with omalizumab is indicated, as 
shown by some studies reporting its preventative capac-
ity [4–6]. However, a negative study was published [7]. 
We describe the case of a patient with repeated SRs to 
honeybee VIT who initially was apparently not respon-
sive to the omalizumab treatment but achieved the com-
plete prevention of SRs by dose increase.
Case presentation
The patient is a woman exposed to honeybee stings 
because her father is a beekeeper. At the age of 22 years 
she experienced a SR of grade 4 severity according to 
Mueller [8] after a single bee sting. Honeybee venom 
hypersensitivity was then diagnosed by skin tests and 
VIT for bee venom was started. However, the treatment 
was withdrawn early, due to repeated SRs to VIT. No 
other stings until the age of 47  years when the patient 
had a further SR (again grade 4 according to Mueller) 
after a bee sting. Patient’s clinical features are reported 
in Table  1. According to clinical history, no additional 
allergy neither other medical conditions were present. 
In 2013, VIT for bee venom was then scheduled by 
honeybee venom from Stallergenes (Antony, France) 
but already during the build-up phase, at the dose of 
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10 mcg of venom, a SR with angioedema of the glot-
tis, cough, itching of hands and feet occurred, requiring 
epinephrine administration for resolution of the symp-
toms (Table  2). Premedication with terfenadine 180  mg 
twice a day in the three days before VIT was attempted 
but anaphylaxis occurred again at the dose of 10 mcg 
and administration of epinephrine was again necessary. 
Therefore, VIT for bee was once more planned using pre-
medication with terfenadine and anti-IgE for preventing 
SRs. Omalizumab 300  mg was administered twice with 
a 14 day interval during the build-up phase of VIT with 
a modified rush schedule at weekly interval (Table  3). 
However, when reaching the dose of 10 mcg the patient 
had cough and dysphagia. Changing the premedication 
to omalizumab plus intravenous hydrocortisone 500 mg, 
intravenous ranitidine 50 mg and cetirizine 10 mg/os, a 
maintenance dose of 200 mcg of bee venom was reached 
in 11 weeks and well tolerated in the following months. 
This suggested to step down omalizumab to 150 mg every 
2  weeks and using oral premedication with prednisone 
25 mg, rupatadine 10 mg and ranitidine 150 mg. VIT and 
omalizumab administrations were set on different days. 
However, when omalizumab was reduced to 150 mg once 
a month a SR requiring epinephrine occurred. Therefore, 
the dose of omalizumab was doubled to 300  mg once a 
month along with the oral premedication with the usual 
drugs letting the patient tolerating the monthly dose of 
200 mcg of bee venom. However, seven months later, the 
same premedication regimen was not able to prevent a 
new SR to VIT. Finally, when increasing the dose of omal-
izumab to 450 mg monthly, 2 days before VIT, preceded 
by oral premedication with prednisone, rupatadine and 
ranitidine 12 and 2  h before VIT, the patient no longer 
suffered from SRs over the last 14  months and is still 
under regular treatment.
Conclusions
VIT is a highly effective treatment but not all patients 
are protected from SRs by the usual maintenance dose of 
100 mcg. Rueff et al. demonstrated that in all patients not 
completely protected from stings a protective dose may 
be individuated, that in rare cases may be as high as 400 
mcg [9].
The case we report shows that also the search of the 
dose of omalizumab able to protect a patient with 
repeated SRs to VIT may be demanding, but this pur-
suit is warranted by the need to provide to this kind of 
patient, by an adequate VIT, the protection from poten-
tially life-threatening reactions. In previous reports, the 
minimal effective dose of omalizumab to protect from 
systemic reactions to VIT was 150  mg [10], thus the 
Table 1 Patient’s clinical features at first visit
* performed in 2015; ** performed in 2016




Previous systemic reactions of grade IV Muller Yes
Number of previous attempts of VIT with HB venom withdrawn for repeated systemic reactions  
during build-up phase
3
Skin test Prick test HB venom: 20 mm
(hystamine: 10 mm)
Total IgE 51 kU/l
s-IgE HB 20.3 U/ml
s-IgE Api m 1 7.93 U/ml
s-IgE Api m 10* 0.00 U/ml
s-IgE CCD 0.00 U/ml
Basal tryptase 2.4 ng/ml
Mastocytosis in bone marrow (biopsy performed)** Absent
KIT mutation** Absent








2 10 Ocular itching
3 5 Anaphylaxis
5 Terfenadine 4.11 None
6 Terfenadine 10 None
7 Terfenadine 10 Anaphylaxis
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search of the protective dose should start from 150 mg, 
with increase to 300  mg and, possibly, to 450  mg in 
case of incomplete protection. The most appropri-
ate combination therapy including also corticosteroids 
and antihistamines is not yet established and needs be 
investigated.
Abbreviations
SR: systemic reaction; VIT: venom immunotherapy; mcg: micrograms; mg: 
milligrams.
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Table 3 Build up phase with administration of omalizumab
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1 150
3 300
4 Terfenadine 4.11 None
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